Načítá se...
A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer
Resistance to current HER2 inhibitors, such as trastuzumab (Ttzm), is a major unresolved clinical problem in HER2-positive BC (HER2-BC). Because HER2 remains overexpressed in drug-resistant HER2-BC cells, we investigated whether PEPD(G278D) can overcome the resistance. PEPD(G278D) is a recombinant e...
Uloženo v:
| Vydáno v: | Sci Transl Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6409101/ https://ncbi.nlm.nih.gov/pubmed/30674653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aav1620 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|